GlaxoSmithKline

We have 3 global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies.

We see partnerships and collaborations with academia, business, charities and individuals as a fundamental part of building a successful, diversified, global healthcare business. Working with outside organisations helps us advance our scientific research and develop products that can address the health needs of people around the world.

Our open innovation strategy is designed to promote change beyond GSK by sharing expertise, resources, intellectual property and know-how with external researchers and the scientific community. Our previous focus was on diseases of the developing world, such as malaria, tuberculosis and parasitic infections and, we are now adapting open innovation models to apply to other areas of great medical need and scientific challenge including infectious, autoimmune disease, immuno-oncology and rare diseases.

We are focusing our global health efforts on fighting infectious diseases that impact children and adolescents in the developing world – in particular, malaria, TB and HIV/AIDs. We know the challenges to address diseases impacting the world’s poorest are too complex for us to tackle alone. Strong partnerships with organisations with complementary expertise can help us deliver our innovations to patients. GSK is committed to collaborating with other healthcare companies and partner organisations to explore new models.

We have committed to partner to improve disease prevention, awareness and access to healthcare services for 12 million people by 2025.